MedPath

Function Preserving Gastrectomy for T1/2 Gastric Cancer Patients

Recruiting
Conditions
Gastrostomy
Gastric Cancer
Interventions
Procedure: Function preserving gastrectomy
Procedure: Standard gastrectomy
Registration Number
NCT03874871
Lead Sponsor
Peking University
Brief Summary

The real world based multi-cohorts study aims to evaluate the safety and effectiveness of function preserving gastrectomy including pylorus-preserving distal gastrectomy, proximal gastrectomy and wedge gastrectomy for T1 and T2 gastric cancer patients.

Detailed Description

Gastric cancer patients with clinical stage T1/2 will be screened for the study. For the patients enrolled, a multidisciplinary discussion will be performed to evaluate the proper gastrectomy for the patients and functional preserving gastrectomy will be considered for the indicated patients. For patients not proper for functional preserving gastrectomy, standard gastrectomies will be suggested. After surgery, a close follow up will be performed. During the study, a thorough data collection will be performed to evaluate the safety and effectiveness of functional preserving gastrectomy and recovery and postoperative function of remnant stomach.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Karnofsky performance over 70%
  • Histologically proven gastric or gastroesophageal joint adenocarcinoma with clinical stage T1-2N0-3M0
  • No severe comorbidity with estimated survival less than 5 years
Exclusion Criteria
  • pregnancy
  • Signs of distant metastases
  • received chemotherapy, radiotherapy, immune therapy
  • received gastrectomy
  • other malignant tumors within 5 years except for cured skin cancer and cervical caner in situ.
  • uncontrolled epilepsy, central nervus system disease or mental disease that affect the compliance of treatment and follow-up
  • severe heart disease
  • organ transplantation that needs immunosuppressor
  • emergency surgery due to hemorrhage, perforation and ileus of gastric cancer

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Function preserving gastrectomyFunction preserving gastrectomyAfter baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients indicated for function preserving gastrectomy (including pylorus preserving gastrectomy, proximal gastrectomy, partial gastrectomy), they will receive the function preserving gastrectomy. After the surgery, a close follow up is performed.
Standard gastrectomyStandard gastrectomyAfter baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients not indicated for function preserving gastrectomy, they will receive standard gastrectomy. After the surgery, a close follow up is performed.
Primary Outcome Measures
NameTimeMethod
R0 resection rate30 days after surgery

Pathologic R0 resection rate with negative proximal and distal margin based on the postoperative pathologic result.

Secondary Outcome Measures
NameTimeMethod
Distribution of metastatic lymph node30 days after surgery

metastatic lymph node number

Quality of life after surgery3 years after surgery

Quality of life evaluated by EORTC-STO22 by questionnaire

postoperative morbidity30 days after surgery

postoperative complication rate according to the clavien-dindo classification

disease free survival3 years after surgery

disease free survival after surgery

overall survival3 years after surgery

overall survival after surgery

remnant stomach function3 years after surgery

volume of remnant stomach

Extent of lymphadenectomy of different gastrectomy30 days after surgery

resected lymph node number

postoperative mortality30 days after surgery

postoperative death rate with 30 days

Trial Locations

Locations (1)

Beijing Cancer Hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath